Novo Nordisk Q2 Profit Beats Forecasts as Firm Raises Outlook

BAGSVÆRD, Denmark — Danish healthcare giant Novo Nordisk announced on Tuesday, August 4, 2026, that its second-quarter financial performance surpassed market expectations, prompting the pharmaceutical company to raise its full-year financial outlook. The Copenhagen-headquartered maker of diabetes and weight-loss medications reported an adjusted operating profit of DKK 33,389 million (approximately $4.87 billion) for Q2 2026, reflecting an 11% increase at constant exchange rates (CER).

The financial report highlights sustained consumer demand for GLP-1 therapies, including Wegovy and Ozempic, even as the drugmaker navigates pipeline adjustments and intense market competition across global markets.

Financial Performance and Quarterly Beat

Novo Nordisk reported adjusted sales of DKK 78,488 million for the second quarter of 2026, representing a 7% year-on-year increase at constant exchange rates. The company's adjusted operating profit reached DKK 33,389 million, outpacing consensus forecasts from industry analysts.

The positive quarterly trend was primarily supported by strong volume expansion in its GLP-1 diabetes and obesity care franchises, alongside favorable US sales rebate adjustments.

Novo Nordisk Q2 2026 Performance Summary (At CER)
• Adjusted Sales: DKK 78,488 million (+7% YoY)
• Adjusted Operating Profit: DKK 33,389 million (+11% YoY)
• Impairment Charges: DKK 6.3 billion (Pipeline intangible assets)
• Monlunabant Asset Write-Down: DKK 4.0 billion

On a reported basis under International Financial Reporting Standards (IFRS), second-quarter operating profit was impacted by DKK 6.3 billion in non-recurring, non-cash impairment charges related to pipeline assets, including a DKK 4.0 billion write-down on the oral small-molecule drug monlunabant.

Additionally, year-on-year comparisons reflected the previous year's DKK 2.6 billion rebate provision reversal associated with the US 340B Drug Pricing Program.

Full-Year Outlook Revision

Driven by sustained growth expectations for GLP-1 products, Novo Nordisk revised its full-year guidance upward. As Novo Nordisk's Q2 profit beats forecasts, raises outlook expectations across European financial markets, the company now projects 2026 adjusted sales growth between 0% and -6% at CER, an improvement from its earlier projection of -4% to -12%.

Similarly, the company updated its full-year adjusted operating profit growth guidance to a range of 0% to -6% at CER, up from the previous forecast of -4% to -12%. On a non-adjusted basis, the midpoints for full-year sales and operating profit growth at CER correspond to approximately 5% and 12%, respectively.

Market Expansion and Commercial Developments

Commercial execution across key markets contributed significantly to the quarterly results. In the United States, uptake of the oral Wegovy pill expanded, exceeding 265,000 weekly prescriptions during July 2026. Internationally, Novo Nordisk rolled out key obesity care offerings across the United Kingdom and the United Arab Emirates, establishing broader geographic reach.

The expanded outlook demonstrates the firm's commercial resilience as Novo Nordisk's Q2 profit beats forecasts, raises outlook indicators, and reassures institutional investors monitoring competition in the global metabolic medicine market.

Impact on Patients, Healthcare Systems, and Investors

For patients and healthcare providers, Novo Nordisk’s solid operational performance indicates continued manufacturing investments to supply GLP-1 treatments globally. Increased production capacity is expected to alleviate past supply constraints, improving medication availability for individuals managing type 2 diabetes and chronic weight management conditions.

For capital markets and investors, the raised guidance provides a clearer trajectory for Novo Nordisk’s earnings durability. While non-cash pipeline impairments reflect inherent risks in drug development, sustained commercial sales provide revenue stability as competition intensifies from rival pharmaceutical manufacturers.

Official Sources Section

The financial metrics and strategic guidance presented in this report are based on regulatory disclosures and official corporate communications:

• Company Announcement: Official Q2 2026 financial report published by
  Novo Nordisk A/S
  on August 4, 2026.

• Regulatory Submissions: Quarterly disclosures filed with Nasdaq Copenhagen and regulatory agencies under European securities regulations.

Quote Section

"According to officials, increased demand for GLP-1 treatments and disciplined operational execution supported second-quarter earnings, enabling the company to elevate its full-year sales and profit guidance despite pipeline impairment adjustments."

Why It Matters

As Novo Nordisk's Q2 profit beats forecasts, raises outlook, the updated performance signals continued expansion in the global obesity and diabetes market. The pharmaceutical sector's top performer remains a critical anchor for healthcare portfolios and European capital markets, where sustained GLP-1 adoption offsets development pipeline write-downs.

Key Facts at a Glance

• Q2 Adjusted Operating Profit: DKK 33,389 million, representing 11% growth at CER.

• Q2 Adjusted Revenue: DKK 78,488 million, up 7% at CER year-on-year.

• Upgraded Guidance: 2026 adjusted sales and operating profit growth revised to 0% to -6% at CER.

• Impairment Charges: DKK 6.3 billion non-cash write-down on intangible pipeline assets.

• Commercial Milestone: Wegovy pill prescriptions exceeded 265,000 weekly in the US.

Frequently Asked Questions (FAQ)

Q1: What were Novo Nordisk's adjusted Q2 2026 financial results?

Novo Nordisk reported adjusted sales of DKK 78,488 million (up 7% at CER) and an adjusted operating profit of DKK 33,389 million (up 11% at CER) for Q2 2026.

Q2: Why did Novo Nordisk raise its full-year 2026 outlook?

The outlook was revised upward due to higher sales expectations for its GLP-1 product portfolio, including Wegovy and Ozempic. Adjusted sales and operating profit growth are now projected at 0% to -6% at CER, up from the prior -4% to -12% guidance.

Q3: What impairment charges did Novo Nordisk record in Q2 2026?

The company recorded DKK 6.3 billion in non-cash impairment charges on pipeline assets, which included DKK 4.0 billion for the drug monlunabant.

Q4: How is the Wegovy pill performing in the market?

In the United States, the Wegovy pill reached over 265,000 total weekly prescriptions by mid-July 2026, alongside initial commercial rollouts in the UK and UAE.

Source: Novo Nordisk Investor Relations Portal and regulatory filings published on August 4, 2026.